We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

233 hedge funds and large institutions have $1.21B invested in Pacira BioSciences in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 84 increasing their positions, 77 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more call options, than puts

Call options by funds: $7.02M | Put options by funds: $2.2M

9% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 77

0.17% less ownership

Funds ownership: 109.34% → 109.17% (-0.17%)

1% less funds holding

Funds holding: 235 → 233 (-2)

3% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 32

4% less capital invested

Capital invested by funds: $1.26B → $1.21B (-$49.7M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
233
Holders Change
-2
Holders Change %
-0.85%
% of All Funds
3.07%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
31
Increased
84
Reduced
77
Closed
32
Calls
$7.02M
Puts
$2.2M
Net Calls
+$4.83M
Net Calls Change
+$3.7M

Top Buyers

Rank Fund Capital Flow
1
PCH
Polar Capital Holdings
United Kingdom
+$22.9M
2
UBS Group
UBS Group
Switzerland
+$15.3M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$14.2M
4
American Century Companies
American Century Companies
Missouri
+$13M
5
EC
EcoR1 Capital
California
+$11.5M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$33.5M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$27.9M
3
Voloridge Investment Management
Voloridge Investment Management
Florida
-$9.99M
4
JP Morgan Chase
JP Morgan Chase
New York
-$7.83M
5
ECM
ExodusPoint Capital Management
New York
-$7.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rafferty Asset Management
251
Rafferty Asset Management
New York
– -$251K -10,092 Closed
FC
252
FORA Capital
Florida
– -$235K -9,457 Closed
GCM
253
Graham Capital Management
Connecticut
– -$224K -9,018 Closed
MCM
254
Massar Capital Management
Connecticut
– -$211K -8,500 Closed
QCG
255
Quadrant Capital Group
Ohio
– -$167K -6,710 Closed
AA
256
Ancora Advisors
Ohio
– -$109K -4,400 Closed
AAM
257
Advisors Asset Management
Colorado
– -$43.1K -1,733 Closed
CCM
258
Coldstream Capital Management
Washington
– -$39.4K -1,585 Closed
Macquarie Group
259
Macquarie Group
Australia
– -$11.7K -469 Closed
HCM
260
Hollencrest Capital Management
California
– -$10.6K -428 Closed
FDCDDQ
261
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$4.72K -190 Closed
CIBC Private Wealth Group
262
CIBC Private Wealth Group
Georgia
– -$2.18K -83 Closed
AP
263
Aspect Partners
Virginia
– -$1.19K -48 Closed
BI
264
Binnacle Investments
Iowa
– -$199 -8 Closed
7 8 9 10
11

PCRX Hedge Fund Activity: Q2 2025 in Review

233 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2025, worth a combined $1.21B — down 4% from $1.26B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of PCRX and 31 opened new positions — a net loss of 1 holder — while 77 trimmed existing stakes and 84 added.

The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $22.9M. The largest seller was Citadel Advisors, exiting entirely with an estimated $33.5M sold.

  • 233 institutional investors held Pacira BioSciences (PCRX) as of Q2 2025, down from 235 in Q1 2025.
  • Funds reported $1.21B of Pacira BioSciences stock for Q2 2025, down 4% quarter-over-quarter.
  • 31 funds opened new Pacira BioSciences positions in Q2 2025 and 32 closed out, a net change of -1 holder.
  • The largest Pacira BioSciences buyer in Q2 2025 was Polar Capital Holdings, an estimated $22.9M added.
  • The largest Pacira BioSciences seller in Q2 2025 was Citadel Advisors, an estimated $33.5M sold.

Based on aggregated 13F filings for Q2 2025.